Two-year Single-Center Real-Life Data of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B Patients in Taiwan

Abstract

Aim: Chronic infection with hepatitis B virus (CHB) is a worldwide disease. The aim of this study was to evaluate the treatment efficacy and renal tolerability of Tenofovir disoproxil fumarate (TDF) in patients with CHB. Method: Data from patients were retrospectively collected from January 2012 to September 2014. The inclusion criteria included CHB, serum HBV DNA > 2000 IU/ml, high serum alanine aminotransferase (ALT), and persistent use of TDF for at least one year. The exclusion criteria included HCV or HIV coinfection. The therapeutic efficacy was recorded at screening and every 6 months thereafter. Results: Among all 100 enrolled subjects, 28 and 24 patients were HBe-positive and treatment-experienced, respectively. The 2-year biochemical response (ALT less than 40 U/L) was 95% to 100%, virologic response (HBV DNA < 20 IU/ml) was 86% to 98%, and serologic response (HBeAg seroloss) was 33%. No cases with HBsAg clearance were detectable. No significant difference existed between treatment-naive and -experienced patients, but those with positive HBe had a poor virological response compared with the negative HBe group (P=0.043). There was no significant change in renal function. Conclusion: TDF treatment was considered as a efficient, safe and well tolerated therapy to CHB individuals.